Americans have long struggled with prescription drug costs that tower above those in other developed nations.
In 2026, a new government initiative promises to change that reality. TrumpRx Unveiled: Can the President’s Website Slash US Prescription Drug Prices? represents the latest attempt to tackle healthcare affordability, but does it deliver on its bold promises or join the graveyard of failed drug pricing reforms?
The launch of TrumpRx.gov on February 6, 2026, marked a significant moment in the ongoing battle against high medication costs[3]. With claims of delivering “massive immediate savings” to millions of Americans, the platform offers discounted prices on popular medications through negotiated deals with major pharmaceutical manufacturers. But as families across the nation navigate this new resource, critical questions emerge about its effectiveness, sustainability, and real-world impact compared to previous initiatives that promised much but delivered little.
Key Takeaways
- 💊 TrumpRx.gov launched February 6, 2026, offering discounted prescription drugs through deals with 16 major pharmaceutical manufacturers
- 💰 Significant price reductions include Ozempic dropping from $1,028 to $350 monthly and Wegovy pill prices falling to as low as $149
- 🏥 No insurance required to access discounts, making medications more accessible to uninsured and underinsured Americans
- ⚖️ Questions remain about long-term sustainability, limited drug selection, and whether this initiative will succeed where past efforts failed
- 🔍 Comparison to alternatives like GoodRx and international importation schemes reveals both advantages and limitations of the government-led approach
Understanding the TrumpRx Initiative: What Makes It Different?
The TrumpRx platform emerged from an executive order signed in May 2025, setting in motion a series of negotiations between the federal government and pharmaceutical companies[4]. Unlike previous attempts at drug price reform that focused on importation from Canada or Medicare negotiation, this initiative takes a direct-to-consumer approach through a government-operated website.
The platform’s development followed a structured timeline:
| Date | Milestone |
|---|---|
| May 2025 | Executive order signed authorizing negotiations |
| July 31, 2025 | Letters sent to major pharmaceutical manufacturers |
| September 30, 2025 | First announcement with 16 initial deals |
| January 2026 | GoodRx pledged price matching for semaglutide products[1] |
| February 6, 2026 | Official public launch of TrumpRx.gov[3] |
What distinguishes TrumpRx from previous initiatives is its voluntary participation model. Rather than mandating price controls or forcing importation channels, the administration negotiated directly with drugmakers to offer reduced prices through a dedicated platform. This approach sidesteps many regulatory hurdles that doomed earlier efforts.
The website functions as a price transparency and discount portal, connecting patients directly with participating pharmacies offering negotiated rates. Users can search for medications, compare prices, and obtain discount cards without providing insurance information[8]. This accessibility factor addresses a critical gap for the estimated 27 million Americans without health insurance.
However, skeptics point to the political motivations behind such initiatives, questioning whether the program represents sustainable healthcare reform or temporary political theater designed to generate favorable headlines.
TrumpRx Unveiled: Price Reductions That Matter to American Families
The most compelling aspect of TrumpRx Unveiled: Can the President’s Website Slash US Prescription Drug Prices? lies in the concrete price reductions announced at launch. For medications that have become household names—particularly weight-loss and diabetes drugs—the savings appear substantial.
Breakthrough Pricing on Popular Medications
Ozempic, the injectable diabetes medication that gained widespread attention for its weight-loss effects, saw its monthly price drop from $1,028 to an average of $350, with some dosages available for as low as $199[4]. This represents a 66% reduction from retail prices that had placed the medication out of reach for many patients.
Similarly, Wegovy—the FDA-approved weight-loss version of semaglutide—experienced dramatic price cuts:
- Injectable Wegovy: From $1,349 to $350 monthly (74% reduction)
- Wegovy pill form: From $1,349 to as low as $149 monthly (89% reduction)[4]
These reductions matter because semaglutide medications have become some of the most sought-after prescriptions in America, with demand far outstripping insurance coverage. Many patients previously paid full retail prices out-of-pocket, making these drugs a luxury item rather than an accessible treatment option.
Beyond Weight Loss: Broader Medication Coverage
While the initial announcement focused heavily on semaglutide products, the platform includes additional medication categories across various therapeutic areas. The 16 participating pharmaceutical manufacturers represent a cross-section of the industry, suggesting broader coverage than initially apparent[4].
The pricing model operates through discount cards and negotiated pharmacy rates, similar to existing programs like GoodRx but with the backing of federal negotiating power. When GoodRx announced it would match Novo Nordisk’s semaglutide prices in January 2026, it validated the competitive pressure TrumpRx created in the marketplace[1].
For American families struggling with healthcare costs, these reductions could translate to thousands of dollars in annual savings. A patient taking Ozempic for diabetes management would save approximately $8,136 annually at the new $350 monthly rate compared to the previous $1,028 price point.
Yet questions persist about whether these prices represent genuine market disruption or simply formalized versions of existing manufacturer discount programs rebranded under a government initiative. The broader economic pressures facing Americans make scrutinizing such claims essential.
How TrumpRx Compares to Past Drug Pricing Failures
TrumpRx Unveiled: Can the President’s Website Slash US Prescription Drug Prices? invites inevitable comparisons to previous attempts at drug price reform that promised transformation but delivered disappointment. Understanding this historical context helps evaluate whether the current initiative represents genuine progress or another false start.
The Canada Importation Dream That Never Materialized
For decades, politicians from both parties championed drug importation from Canada as a silver bullet for high prescription costs. The logic seemed sound: identical medications cost 40-60% less across the northern border, so why not allow Americans to access those prices?
Multiple attempts to create legal importation pathways failed due to:
- Safety concerns raised by the FDA about supply chain integrity
- Pharmaceutical industry opposition and legal challenges
- Canadian government resistance to becoming America’s pharmacy
- Logistical complexities of verifying medication authenticity
- Limited Canadian supply unable to meet American demand
Despite executive orders, proposed legislation, and state-level initiatives, large-scale Canadian importation never became reality. The most recent attempt under the previous administration resulted in a single state (Florida) receiving approval for a limited pilot program that has yet to launch meaningfully.
Medicare Negotiation: Slow Progress on Limited Drugs
The Inflation Reduction Act’s Medicare drug negotiation provisions represented a legislative breakthrough after years of failed attempts. However, the program’s limited scope—covering only 10 drugs initially—and delayed implementation timeline (with negotiated prices not taking effect until 2026) highlight the difficulty of achieving rapid, comprehensive reform through traditional channels.
TrumpRx’s advantage lies in its immediate implementation without requiring congressional approval or navigating Medicare’s complex regulatory framework. By working directly with manufacturers through voluntary agreements, the initiative bypassed the political gridlock that has paralyzed other reform efforts.
What Makes TrumpRx Different (And What Doesn’t)
Several factors distinguish the current approach:
✅ Immediate availability rather than multi-year implementation timelines
✅ No insurance requirement, expanding access beyond Medicare beneficiaries
✅ Voluntary manufacturer participation avoiding legal challenges
✅ Direct-to-consumer platform leveraging modern technology
However, concerning similarities to past failures include:
❌ Limited drug selection compared to comprehensive reform
❌ Dependence on manufacturer goodwill rather than structural change
❌ Uncertain long-term sustainability beyond the current administration
❌ No mechanism to prevent future price increases on non-participating drugs
The political environment surrounding such initiatives often creates skepticism about whether policy changes will endure beyond election cycles.
The Real-World Impact: Who Benefits Most from TrumpRx?
Evaluating TrumpRx Unveiled: Can the President’s Website Slash US Prescription Drug Prices? requires examining which Americans actually benefit from the platform and which populations remain underserved by this approach.
Uninsured and Underinsured Americans: The Primary Beneficiaries
The 27 million uninsured Americans represent the demographic most likely to benefit from TrumpRx discounts[1]. Without insurance coverage or pharmacy benefit managers negotiating on their behalf, these individuals typically pay full retail prices that can consume significant portions of household budgets.
For this population, TrumpRx offers:
- No eligibility requirements beyond being a U.S. resident
- No monthly premiums or enrollment fees
- Immediate access to discounted prices
- Price transparency before visiting the pharmacy
Similarly, underinsured Americans—those with high-deductible plans or coverage that excludes certain medications—gain a valuable tool for reducing out-of-pocket costs. When insurance doesn’t cover a needed medication or requires prohibitive copayments, TrumpRx provides an alternative pathway.
Medicare and Medicaid Recipients: Limited Additional Value
Conversely, Americans already enrolled in Medicare Part D or Medicaid programs may see minimal benefit from TrumpRx. These government programs already negotiate drug prices and provide coverage that often exceeds the discounts available through the new platform.
For Medicare beneficiaries, the Inflation Reduction Act’s provisions—including the $2,000 annual out-of-pocket cap taking effect in 2025 and negotiated prices on select drugs—likely offer better overall value than TrumpRx for covered medications.
Geographic and Demographic Considerations
The platform’s effectiveness varies based on:
Geographic location: Rural Americans with limited pharmacy options may find fewer participating locations, while urban residents enjoy broader access.
Technology access: The digital-first approach assumes internet connectivity and digital literacy, potentially excluding elderly or low-income populations without reliable technology access.
Medication needs: Patients requiring medications included in the initial 16 manufacturer agreements benefit immediately, while those needing other drugs must wait for expanded coverage.
The challenges facing various American communities extend beyond prescription costs, but medication affordability remains a critical component of overall financial security.
Chronic Disease Patients: Long-Term Savings Potential
Americans managing chronic conditions requiring ongoing medication represent another key beneficiary group. For diabetes patients needing continuous Ozempic treatment, the monthly savings of $678 (from $1,028 to $350) accumulate to $8,136 annually—a potentially life-changing amount for middle-class families.
However, sustainability concerns arise: Will these negotiated prices remain stable? Can patients rely on TrumpRx availability for years of chronic disease management? The absence of contractual guarantees beyond the current administration creates uncertainty for long-term planning.
Limitations and Concerns: The Fine Print of TrumpRx
While headlines celebrate dramatic price reductions, a thorough examination of TrumpRx Unveiled: Can the President’s Website Slash US Prescription Drug Prices? reveals significant limitations that temper initial enthusiasm.
Narrow Drug Selection Compared to Market Needs
The platform’s 16 participating manufacturers represent only a fraction of the pharmaceutical industry[4]. Thousands of prescription medications remain excluded from the program, meaning most Americans will still need traditional insurance or discount programs for the majority of their medication needs.
The heavy focus on semaglutide products (Ozempic and Wegovy) in promotional materials suggests the initiative prioritizes high-profile, expensive medications that generate favorable press coverage rather than comprehensive formulary development. Common medications for conditions like hypertension, depression, or antibiotics receive less attention despite affecting larger patient populations.
Pharmacy Participation and Accessibility Questions
TrumpRx functions as a discount card program requiring participating pharmacies to honor negotiated prices[8]. The extent of pharmacy network participation remains unclear, raising questions about:
- Will major chains like CVS, Walgreens, and Walmart participate uniformly?
- How will independent pharmacies handle the administrative burden?
- What happens when a patient’s preferred pharmacy doesn’t participate?
- Are mail-order options available for patients in pharmacy deserts?
These operational details significantly impact the program’s practical utility for everyday Americans.
Lack of Legal and Regulatory Protections
Unlike Medicare or Medicaid, TrumpRx operates through voluntary manufacturer agreements without statutory authority mandating continued participation or price stability[2]. This creates several vulnerabilities:
🚨 Manufacturers can withdraw from agreements at any time
🚨 Prices can increase once initial agreements expire
🚨 No legal recourse for patients if the program ends abruptly
🚨 Future administrations may not continue the initiative
The absence of congressional legislation underpinning TrumpRx means the entire program exists at the discretion of executive action—a fragile foundation for Americans planning long-term healthcare budgets.
Privacy and Data Security Considerations
The TrumpRx.gov platform collects personal health information from users searching for medications and obtaining discount cards[8]. Questions about data security, privacy protections, and potential information sharing with third parties deserve scrutiny.
Federal health privacy regulations (HIPAA) may not fully apply to this platform depending on its operational structure, potentially creating gaps in protection compared to traditional healthcare providers and insurers.
Competition with Existing Discount Programs
GoodRx, SingleCare, and other established prescription discount platforms have operated successfully for years, often delivering comparable or better prices than TrumpRx on many medications[1]. When GoodRx announced it would match TrumpRx’s semaglutide prices, it demonstrated that competitive market forces already existed to deliver similar discounts without government intervention.
This raises fundamental questions: Does TrumpRx represent genuine innovation, or does it duplicate existing private-sector solutions while adding a government brand? The answer significantly affects assessments of the program’s value proposition.
Understanding broader concerns about government initiatives and their effectiveness helps contextualize skepticism about TrumpRx’s long-term viability.
Expert Perspectives: Healthcare Industry Reactions to TrumpRx
The healthcare industry’s response to TrumpRx Unveiled: Can the President’s Website Slash US Prescription Drug Prices? reveals the complex dynamics between pharmaceutical manufacturers, pharmacy benefit managers, insurers, and patient advocacy groups.
Pharmaceutical Industry: Cautious Cooperation
Major drugmakers participating in TrumpRx agreements have issued carefully worded statements emphasizing their commitment to patient access while avoiding explicit endorsement of the program’s political framing[6]. This cautious cooperation reflects several considerations:
Public relations value: Participating allows manufacturers to demonstrate responsiveness to affordability concerns without fundamental business model changes.
Limited financial impact: The discounts often formalize existing patient assistance programs or match prices already available through manufacturer coupons, minimizing revenue loss.
Regulatory relationship: Cooperation with administration initiatives may benefit companies in future regulatory interactions or merger approvals.
However, industry analysts note that voluntary participation can evaporate quickly if political winds shift or if the program begins threatening core profitability. The lack of binding commitments beyond initial agreements creates uncertainty about sustained manufacturer engagement.
Pharmacy Benefit Managers: Threatened Intermediaries
Pharmacy benefit managers (PBMs)—the middlemen who negotiate drug prices on behalf of insurers—face potential disruption from TrumpRx’s direct-to-consumer model. By bypassing PBMs entirely, the platform challenges their role in the healthcare ecosystem.
PBM industry groups have remained relatively quiet publicly, but behind-the-scenes concerns focus on:
- Precedent-setting for government intervention in drug pricing
- Potential expansion threatening their negotiating leverage
- Competition for patients who might abandon insurance coverage for TrumpRx discounts
The PBM industry’s influence in Washington suggests potential future lobbying efforts to limit TrumpRx’s scope or effectiveness.
Patient Advocacy Organizations: Measured Optimism
Groups representing patients with chronic diseases have offered qualified support for TrumpRx, welcoming price reductions while noting limitations[1]. Common themes in advocacy responses include:
✅ Appreciation for immediate relief on high-cost medications
⚠️ Concerns about narrow drug selection
⚠️ Questions about sustainability beyond current administration
⚠️ Calls for comprehensive legislative reform rather than executive actions
Patient advocates emphasize that while TrumpRx helps some Americans, it doesn’t address systemic issues driving high drug prices: patent protections, market exclusivity, lack of price negotiation authority, and profit-maximizing pharmaceutical business models.
Healthcare Economists: Skepticism About Long-Term Impact
Academic experts analyzing TrumpRx express skepticism about its capacity to fundamentally alter drug pricing dynamics[2]. Economic analyses highlight several concerns:
Limited market pressure: With only 16 manufacturers participating in a voluntary program, competitive pressure on the broader pharmaceutical industry remains minimal.
Substitution rather than reduction: Patients may shift from existing discount programs to TrumpRx without creating new affordability, merely redistributing existing discounts under government branding.
Sustainability questions: Without statutory authority or permanent funding, the program’s future depends entirely on executive branch priorities that change with elections.
Opportunity cost: Resources devoted to TrumpRx might deliver greater impact if directed toward comprehensive legislative reform addressing root causes of high drug prices.
These expert perspectives suggest that while TrumpRx provides tangible benefits to some Americans, it falls short of the transformative change needed to align U.S. drug prices with international standards.
Actionable Steps: How Americans Can Maximize TrumpRx Benefits
For families seeking to reduce prescription costs, understanding how to effectively use TrumpRx Unveiled: Can the President’s Website Slash US Prescription Drug Prices? alongside other resources maximizes potential savings.
Step-by-Step Guide to Using TrumpRx.gov
1. Visit the official website: Navigate to TrumpRx.gov (verify the .gov domain to avoid scam sites)[8]
2. Search for your medication: Enter the drug name, strength, and quantity prescribed by your doctor
3. Compare prices: Review available prices at participating pharmacies in your area
4. Obtain discount card: Download or print the discount card for your selected medication
5. Present at pharmacy: Show the discount card when filling your prescription at a participating location
6. Verify final price: Confirm the discounted price before completing the transaction
Comparing TrumpRx with Alternative Discount Programs
Smart consumers should compare multiple discount sources before filling prescriptions:
| Platform | Advantages | Considerations |
|---|---|---|
| TrumpRx | Government-negotiated prices, no fees | Limited drug selection, uncertain longevity |
| GoodRx | Broad drug coverage, established network | Prices vary, data privacy concerns |
| Manufacturer Coupons | Significant discounts on specific brands | Eligibility restrictions, expiration dates |
| Pharmacy Discount Programs | Convenient if already shopping there | Limited to that pharmacy chain |
For maximum savings, check all available options for each prescription. The lowest price source may differ by medication, dosage, and location.
When to Use Insurance vs. TrumpRx
Counterintuitively, insurance coverage doesn’t always provide the best price. Consider using TrumpRx or other discount programs when:
- Your medication isn’t covered by your insurance formulary
- Your deductible hasn’t been met and you’re paying full price
- Your copay exceeds the TrumpRx discounted price
- You’re in the Medicare Part D “donut hole” coverage gap
Important: If you use a discount card instead of insurance, that purchase typically won’t count toward your deductible or out-of-pocket maximum. Track these decisions carefully for overall healthcare budgeting.
Avoiding TrumpRx Scams and Fraud
The program’s high profile creates opportunities for scammers to exploit unsuspecting patients. Protect yourself by:
🛡️ Only visiting TrumpRx.gov (official .gov domain)
🛡️ Never providing credit card information to access discounts
🛡️ Avoiding unsolicited emails or calls claiming to represent TrumpRx
🛡️ Verifying pharmacy participation directly before visiting
🛡️ Reporting suspected fraud to the FTC or state attorney general
The prevalence of various scams targeting Americans makes vigilance essential when using any new healthcare program.
Advocating for Expanded Coverage
Patients whose medications aren’t currently covered by TrumpRx can take action:
📧 Contact the TrumpRx.gov feedback system requesting specific drug additions
📧 Reach out to pharmaceutical manufacturers directly about participation
📧 Engage with patient advocacy organizations in your disease community
📧 Communicate with elected representatives about comprehensive drug pricing reform
While individual advocacy may not produce immediate results, collective patient voices have historically influenced healthcare policy decisions.
The Future of TrumpRx: Sustainability and Expansion Questions
As Americans evaluate TrumpRx Unveiled: Can the President’s Website Slash US Prescription Drug Prices?, questions about the program’s future trajectory loom large over its current benefits.
Political Sustainability Beyond 2026
The most significant uncertainty surrounding TrumpRx involves its political lifespan. As an initiative created through executive action rather than legislation, the program could be:
- Modified substantially by the current administration based on performance data
- Eliminated entirely by a future administration with different healthcare priorities
- Expanded significantly if deemed politically successful
- Codified into law if Congress passes supporting legislation
Patients building long-term treatment plans around TrumpRx prices face inherent uncertainty about whether these discounts will remain available in 2027, 2028, and beyond. This instability contrasts with statutory programs like Medicare that persist across administrations.
Potential for Expanded Drug Coverage
The initial launch covering 16 manufacturers represents either a starting point for gradual expansion or the program’s maximum scope, depending on future developments[4]. Factors influencing expansion include:
Manufacturer willingness: Additional drugmakers may join if they perceive competitive disadvantage or public relations benefits from participation.
Political pressure: Public demand for specific medications could pressure manufacturers to participate or face regulatory consequences.
Operational capacity: The government’s ability to negotiate, implement, and administer additional agreements may limit expansion speed.
Budget considerations: While TrumpRx doesn’t involve direct government subsidies, administrative costs and potential future funding mechanisms could constrain growth.
Optimistic projections envision hundreds of medications eventually covered, while skeptics predict the program will stagnate at current levels once initial political momentum fades.
Integration with Broader Healthcare Reform
TrumpRx exists within a larger landscape of healthcare policy debates including:
- Medicare negotiation expansion under the Inflation Reduction Act
- Potential legislation addressing pharmacy benefit manager practices
- International reference pricing proposals
- Patent reform to accelerate generic competition
- Transparency requirements for drug pricing
The program’s long-term significance depends partly on whether it catalyzes comprehensive reform or serves as a substitute preventing more substantial changes. Patient advocates worry that TrumpRx’s modest successes might reduce political urgency for addressing systemic issues.
Lessons from International Drug Pricing Models
Countries with lower prescription drug costs typically employ mechanisms absent from TrumpRx:
Government price setting: Direct authority to establish maximum allowable prices
Bulk purchasing: National health systems negotiating for entire populations
Reference pricing: Linking domestic prices to international averages
Therapeutic substitution: Encouraging use of equally effective cheaper alternatives
TrumpRx’s voluntary, market-based approach differs fundamentally from these models, suggesting its price reduction potential may remain limited compared to international standards.
The broader global context of policy approaches illustrates how different governmental philosophies produce dramatically different outcomes in similar policy domains.
Conclusion: TrumpRx as Incremental Progress, Not Revolutionary Change
TrumpRx Unveiled: Can the President’s Website Slash US Prescription Drug Prices? delivers a complex answer: yes, for some Americans and some medications, but with significant limitations that prevent it from fundamentally transforming the U.S. drug pricing landscape.
The platform’s genuine achievements deserve recognition:
✅ Immediate price reductions on expensive medications like Ozempic and Wegovy
✅ No-cost access for uninsured Americans without eligibility barriers
✅ Increased price transparency and consumer empowerment
✅ Competitive pressure prompting matching discounts from private companies
✅ Demonstration that voluntary manufacturer cooperation can produce savings
However, substantial limitations temper enthusiasm:
❌ Narrow drug selection covering a tiny fraction of prescription medications
❌ Uncertain sustainability dependent on executive branch priorities
❌ Lack of statutory authority or legal protections for patients
❌ Limited impact on systemic factors driving high U.S. drug prices
❌ Potential substitution of existing discounts rather than new savings creation
For American families struggling with prescription costs, TrumpRx represents a useful tool worth exploring alongside other discount programs, manufacturer coupons, and insurance options. The platform may deliver meaningful savings for patients needing covered medications, particularly those without insurance coverage.
Yet TrumpRx falls short of the comprehensive reform needed to align U.S. drug prices with international standards. Voluntary manufacturer agreements cannot substitute for legislative changes addressing patent protections, market exclusivity, pharmacy benefit manager practices, and fundamental pharmaceutical pricing dynamics.
Next Steps for Consumers
Immediate actions:
- Visit TrumpRx.gov to check if your medications are covered
- Compare TrumpRx prices with your insurance copays and other discount programs
- Use whichever option provides the lowest out-of-pocket cost
- Stay informed about program expansions and changes
Longer-term advocacy:
- Support comprehensive drug pricing legislation addressing root causes
- Engage with patient advocacy organizations in your disease community
- Communicate with elected representatives about healthcare priorities
- Share experiences with TrumpRx to inform policy discussions
The question “Can the President’s Website Slash US Prescription Drug Prices?” receives a qualified yes—it can reduce some prices for some patients. Whether this incremental progress evolves into transformative change or remains a limited executive initiative depends on future political will, manufacturer cooperation, and sustained public pressure for comprehensive healthcare reform.
American families deserve better than navigating a complex patchwork of discount programs, manufacturer coupons, and variable insurance coverage. While TrumpRx adds another option to this confusing landscape, the ultimate goal should remain systemic reform ensuring affordable medication access for all Americans regardless of insurance status, income level, or political administration.
References
[1] Trumprx Launch Brings Savings And Uncertainty – https://www.ajmc.com/view/trumprx-launch-brings-savings-and-uncertainty
[2] Trumprx Makes Its Debut 00767681 – https://www.politico.com/newsletters/prescription-pulse/2026/02/06/trumprx-makes-its-debut-00767681
[3] President Trump Launches Trumprx Gov Delivering Massive Immediate Savings To Millions Of Americans – https://www.whitehouse.gov/articles/2026/02/president-trump-launches-trumprx-gov-delivering-massive-immediate-savings-to-millions-of-americans/
[4] Fact Sheet President Donald J Trump Launches Trumprx Gov To Bring Lower Drug Prices To American Patients – https://www.whitehouse.gov/fact-sheets/2026/02/fact-sheet-president-donald-j-trump-launches-trumprx-gov-to-bring-lower-drug-prices-to-american-patients/
[5] Story – https://abcnews.go.com/Politics/trump-unveil-trumprx-website-americans-buy-lower-priced/story?id=129895605
[6] biopharmadive – https://www.biopharmadive.com/news/trump-rx-drug-prices-discount-white-house/811576/
[7] Oig Clears Path For Lower Cost Prescription Drugs – https://www.hhs.gov/press-room/oig-clears-path-for-lower-cost-prescription-drugs.html
[8] trumprx.gov – https://trumprx.gov
Some content and illustrations on GEORGIANBAYNEWS.COM are created with the assistance of AI tools.
GEORGIANBAYNEWS.COM shares video content from YouTube creators under fair use principles. We respect creators’ intellectual property and include direct links to their original videos, channels, and social media platforms whenever we feature their content. This practice supports creators by driving traffic to their platforms.
